Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
USPH Stock Forecast 2025-2026
$74.07
Current Price
$1.13B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to USPH Price Targets
+52.6%
To High Target of $113.00
+46.5%
To Median Target of $108.50
+32.3%
To Low Target of $98.00
USPH Price Momentum
+2.5%
1 Week Change
+6.8%
1 Month Change
-30.4%
1 Year Change
-16.5%
Year-to-Date Change
-31.5%
From 52W High of $108.14
+18.0%
From 52W Low of $62.77
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching US Physical Therapy (USPH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on USPH and similar high-potential opportunities.
Latest USPH Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, USPH has a bullish consensus with a median price target of $108.50 (ranging from $98.00 to $113.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $74.07, the median forecast implies a 46.5% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Constantine Davides at JMP Securities, projecting a 52.6% upside. Conversely, the most conservative target is provided by Michael Petusky at Barrington Research, suggesting a 32.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
USPH Analyst Ratings
6
Buy
1
Hold
0
Sell
USPH Price Target Range
Low
$98.00
Average
$108.50
High
$113.00
Current: $74.07
Latest USPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for USPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 22, 2025 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $113.00 |
| Mar 19, 2025 | JP Morgan | Calvin Sternick | Overweight | Maintains | $110.00 |
| Feb 28, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $98.00 |
| Dec 16, 2024 | B of A Securities | Joanna Gajuk | Buy | Upgrade | $115.00 |
| Dec 16, 2024 | JMP Securities | Constantine Davides | Market Outperform | Initiates | $113.00 |
| Dec 3, 2024 | JP Morgan | Calvin Sternick | Overweight | Maintains | $120.00 |
| Nov 21, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Nov 7, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Oct 9, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Oct 7, 2024 | B of A Securities | Joanna Gajuk | Neutral | Downgrade | $90.00 |
| Sep 20, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Aug 15, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| May 9, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $122.00 |
| Mar 13, 2024 | JP Morgan | Calvin Sternick | Overweight | Maintains | $117.00 |
| Mar 1, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $122.00 |
| Jan 3, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $120.00 |
| Nov 17, 2023 | JP Morgan | Calvin Sternick | Overweight | Maintains | $99.00 |
| Nov 9, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $111.00 |
| Sep 22, 2023 | JP Morgan | Calvin Sternick | Overweight | Initiates | $108.00 |
| Sep 19, 2023 | CJS Securities | Larry Solow | Market Outperform | Upgrade | $0.00 |
U.S. Physical Therapy Inc. (USPH) Competitors
The following stocks are similar to US Physical Therapy based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
USPH
US Physical Therapy
mkt cap
1.13B
U.S. Physical Therapy Inc. (USPH) Financial Data
U.S. Physical Therapy Inc. has a market capitalization of $1.13B with a P/E ratio of 34.0x. The company generates $692.32M in trailing twelve-month revenue with a 4.8% profit margin.
Revenue growth is +18.1% quarter-over-quarter, while maintaining an operating margin of +8.3% and return on equity of +6.6%.
Valuation Metrics
Market Cap
$1.13B
Enterprise Value
$1.66B
P/E Ratio
34.0x
PEG Ratio
25.5x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+18.1%
Gross Margin
+18.0%
Operating Margin
+8.3%
Net Margin
+4.8%
EPS Growth
+23.0%
Financial Health
Cash/Price Ratio
+3.5%
Current Ratio
1.2x
Debt/Equity
40.5x
ROE
+6.6%
ROA
+4.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
U.S. Physical Therapy Inc. (USPH) Business Model
About U.S. Physical Therapy Inc.
What They Do
Provides outpatient physical therapy services.
Business Model
The company operates a network of outpatient physical therapy clinics, generating revenue through rehabilitation services for patients recovering from various conditions. It partners with hospitals, physicians, and employers to deliver tailored therapy solutions, ensuring a steady stream of clients and a diverse revenue base.
Additional Information
U.S. Physical Therapy Inc. is headquartered in Houston, Texas, and plays a vital role in the healthcare sector. The company is well-positioned to benefit from the increasing demand for physical therapy services due to an aging population and the growing awareness of rehabilitation therapy's benefits.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
4,034
CEO
Mr. Christopher J. Reading
Country
United States
IPO Year
1992
Website
www.usph.comU.S. Physical Therapy Inc. (USPH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
U.S. Physical Therapy (USPH) Beats Q1 Earnings Estimates (Revised)
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 4.35% and 3.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 08, 2025
By Zacks Equity Research
Tale of the Tape
U.S. Physical Therapy (USPH) Lags Q1 Earnings Estimates
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -10.87% and 3.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
U.S. Physical Therapy, Inc. will hold its Q1 2025 earnings conference call on May 8, 2025, at 10:30 AM ET, featuring key executives and financial analysts from major firms.
Why It Matters
The earnings conference call provides insights into U.S. Physical Therapy's financial performance, strategic direction, and responses to analyst inquiries, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
U.S. Physical Therapy (USPH) reported Q3 earnings of $0.48 per share, surpassing the Zacks Estimate of $0.46, but down from $0.51 per share year-over-year.
Why It Matters
USPH's earnings beat estimates, indicating solid performance, but a year-over-year decline may raise concerns about future growth potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
U.S. Physical Therapy, Inc. (NYSE: USPH) reported Q1 2025 adjusted EBITDA of $19.5 million, up $2.8 million from the previous year.
Why It Matters
USPH's Q1 financial results show a significant increase in adjusted EBITDA, indicating strong operational performance and potential for growth, which can positively influence stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
U.S. Physical Therapy (USPH) reported Q3 earnings of $0.41 per share, below the Zacks estimate of $0.46 and down from $0.51 per share year-over-year.
Why It Matters
USPH's earnings miss signals potential operational challenges, which may lead to decreased investor confidence and affect stock performance negatively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Marketdata LLC's report on "U.S. Physical Therapy Clinics: An Industry Analysis" is now available on ResearchAndMarkets.com as of May 2, 2025.
Why It Matters
The report on U.S. Physical Therapy Clinics provides insights into industry trends, growth potential, and competitive landscape, influencing investment decisions in healthcare sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
U.S. Physical Therapy, Inc. (NYSE: USPH) has acquired an outpatient home care practice through its 50%-owned subsidiary, MSO Metro, LLC, which generates approximately $2.1 million in annual revenues.
Why It Matters
The acquisition enhances U.S. Physical Therapy's service offerings and revenue streams, potentially boosting overall growth and profitability.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About USPH Stock
What is U.S. Physical Therapy Inc.'s (USPH) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, U.S. Physical Therapy Inc. (USPH) has a median price target of $108.50. The highest price target is $113.00 and the lowest is $98.00.
Is USPH stock a good investment in 2025?
According to current analyst ratings, USPH has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $74.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for USPH stock?
Wall Street analysts predict USPH stock could reach $108.50 in the next 12 months. This represents a 46.5% increase from the current price of $74.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is U.S. Physical Therapy Inc.'s business model?
The company operates a network of outpatient physical therapy clinics, generating revenue through rehabilitation services for patients recovering from various conditions. It partners with hospitals, physicians, and employers to deliver tailored therapy solutions, ensuring a steady stream of clients and a diverse revenue base.
What is the highest forecasted price for USPH U.S. Physical Therapy Inc.?
The highest price target for USPH is $113.00 from Constantine Davides at JMP Securities, which represents a 52.6% increase from the current price of $74.07.
What is the lowest forecasted price for USPH U.S. Physical Therapy Inc.?
The lowest price target for USPH is $98.00 from Michael Petusky at Barrington Research, which represents a 32.3% increase from the current price of $74.07.
What is the overall USPH consensus from analysts for U.S. Physical Therapy Inc.?
The overall analyst consensus for USPH is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $108.50.
How accurate are USPH stock price projections?
Stock price projections, including those for U.S. Physical Therapy Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 5:34 AM UTC